Lustro Comments

Discuss this Deal with other Investors



QMed's flagship product, Quest, is a hardware and software solution that is designed to enable device manufacturers, distributors and care providers with inventory visibility by data and analytics to ensure more informed decision making, better resource management and improved outcomes.

Claim My Business
Security Type
Common Stock
Min Investment
Middletown, RI
Offering Date
September 06, 2023
Expected Close Date
November 17, 2023
Target Raise
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

QMed Innovations is a wireless asset management and data aggregation company formed to develop and commercialize technologies that enable medical device manufacturers, hospitals, labs, and distributors to track surgical trays and instruments, manage inventories, and mitigate loss and expense of inefficiency in the manufacturer to surgical procedure value chain.

QMed Innovations, Inc. has patented technology to track medical device kits with its Quest product, which is a hardware and software solution sold to other companies in the medical device industry. The company’s flagship Quest product offers stakeholders 100% asset visibility, optimized inventory, and capital investment in healthcare surgical environments. It is one of the only autonomous Cellular IoT solutions designed to withstand the rigors of asset processing in healthcare surgical environments. Quest analytics aims to provide daily location updates, historical inventory data, and maintenance tracking; enable ease of regulatory compliance; and enhance recall management. The company’s business model includes an initial trial or test period which provides the customer field use of a sufficient amount of Quest devices and then the company works with these customers to develop a deployment schedule for additional devices sufficient to meet their inventory requirements. The revenue model is license and SaaS-based. The company uses licensing fees and volume of orders to fix the monthly SaaS fees. The contract term is typically 3 years. The primary customers for Quest products are OEMs and distributors. 

The orthopedic devices market is approximately $28B in the United States, inclusive of joint reconstruction, spinal devices, trauma devices, arthroscopy devices, and orthobiologic devices throughout in over 6,000 hospitals, clinics, labs, and ambulatory surgical centers. Proprietary instrument kits (surgical tools) are used for every surgical case. The global surgical kits market accounted for revenue of $18B in 2022 and is projected to increase to $22.5B by the end of 2026, representing a CAGR of 6.6% for the forecast period. Given the augmenting number of surgeries due to the increasing prevalence of orthopedic disorders and traumatic injuries and the rapid rise in the aging population, the market for surgical tool management is expected to grow. 

The product is fairly new in the market and has entered into trials with several of the industry’s largest and key firms including initial orders from Anika, Accelus, Innovasys, and Medtronic. The company had revenue of $57.27k in 2022 against $16.82k in 2021. The gross margin was 80.48% in 2022 as compared to 46.87% in 2021. The net loss stood at $3.12M in 2022 and $1.69M in 2021.

Use of Proceeds

The Company plans to use the proceeds on payroll, research and development, inventory, marketing, legal and professional, administrative, and platform fees.

Management Team / Advisory Board Bios

The management is good.

Victor Nunes, CEO
Victor is the CEO and heads the technical and marketing efforts at QMed as well as the launch of Quest. He also oversees investor relations and fundraising. Vic has spent over 30 years in the orthopedic industry as an executive responsible for two global operations and supply chain organizations, among them Depuy Synthes, a Johnson & Johnson company. This is his first startup and he works full-time at the company. 

Shelby Kornbluth, VP of Product Development
Shelby is responsible for all aspects of the company’s product development, from concept engineering through commercialization. She has 25 years of experience in R&D and program management spent at Johnson & Johnson, Olympus Surgical Technologies, and Genzyme. During her two decades at Johnson & Johnson, Shelby assumed various roles of increasing responsibility and eventually took on the position of Director of R&D for the Neuro division.

Jeffrey C. Adam, CPA, CFO
Jeff is the fractional CFO and handles all financial aspects of the company, including financial reporting and investor relations. He is the managing partner of Adam Financial LLP, a boutique CPA firm, and has over 40 years of financial, operational, and strategic experience in public accounting, and has served as a CFO in various industries.

Valuation Notes

The Company had entered into a 36-month note payable for $100k which increased to $300k on January 31, 2023, on which interest is charged at 12% per annum and payable quarterly. The company has valued itself at $14.80M pre-money. The company looks overvalued.

Amount Raised : $700
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

Common stock is a security that represents ownership in a corporation.

Research Reports

No reports have been submitted

Become a Reporter